Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex

J Pain
June 2005
https://pubmed.ncbi.nlm.nih.gov/15943961/

Off-label, Low-Dose Naltrexone for Refractory Chronic Low Back Pain

Pain Med
May 2014
https://europepmc.org/article/med/24967470

Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo

Int Immunopharmacol
September 2020
https://pubmed.ncbi.nlm.nih.gov/32585612/

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management  (Abstract)

Molecules
11 Sept 2020
https://pubmed.ncbi.nlm.nih.gov/32932935/

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study (Abstract)

Front Pharmacol
18 Sept 2020
https://pubmed.ncbi.nlm.nih.gov/33071790/

Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA (Abstract)

ACS Pharmacol Transl Sci
27 July 2020
https://pubmed.ncbi.nlm.nih.gov/33073190/

Low-Dose Naltrexone: An Inexpensive Medicine for Many Ills?

Medscape Medical News
11 Mar 2020
https://www.medscape.com/viewarticle/926611?src=WNL_trdalrt_201027_MSCPEDIT&uac=267476HJ&impID=2640101&f

LDN Research Trust on Vimeo.

Dr Asher Goldstein’s presentation on Pain at The 2019 Pain Seminar.

Dr Goldtsein talks about the Opioid Epidemic in America, stating that over 1.4 million Americans misused opioids in 2017.

Samyadev Datta, MD, FRCA - LDN in Pain Management (2017 Conference) (LDN, low dose naltrexone)

In this presentation Dr Datta explains the science behind pain management, and how through his wealth of experience in the medical sector he has identified inflammation as a primary cause of pain and LDN to an effective solution.